Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology

NCT02401880 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Linagliptin
OTHER: Placebo
DRUG: Empagliflozin

Sponsor

Profil Institut für Stoffwechselforschung GmbH